Kermode Biotechnologies

Providing Innovative Medicines for Swine Diseases to Cover an Unmet Global Need for Herd Protection

Print
Claim My Business
View on Wefunder
Security Type
CAFES
Categories
Financial Services, Healthcare & Medical
Min Investment
$100
Location
Denver, , CO
No. Investors
13
Website
kermodebio.com

Key Deal Facts

A Summit Impact Partners Venture fund portfolio company. $1.5M raised from China & US family offices
No Pigs = No Bacon: Developing AI Medicines to Protect $60B Global Pork Supply from Deadly Viruses.
$2B addressable market, targeting 15% of 850M+ global swine representing a massive ROI opportunity.
5 vaccine candidates in pre-clinical trials, 2 ready for challenge.
Team from Boehringer, Cornell, Danisco, GSK and NIH - with decades of expertise.
7 patents, 20+ filings, protection through 2043 in key markets.
Revolutionary 'dominant negative' approach where others failed.
DIVA compliant immunotherapy to protect $23B US pork trade certification.

Management Team / Advisory Board Bios

Notable Angel
Raised $25k or more from a notable angel investor, Dalu Chen MBAChairmanChairman Dalu Chen brings unicorn-spotting track record (SpaceX, NIO investor) plus 22 years at elite China funds: NewMargin Ventures (top 10 VC), Bridge Capital (top 50 PE), now focused on biotech impact., Thomas MalcolmCEO & CSOSerial biotech entrepreneur CEO: 25 years virus/molecular biology expertise, raised $25M+ in biotech seed funding, founded multiple companies including cancer therapeutics venture. Advanced CRISPR, vaccines, drug delivery breakthroughs., Edward Robb - DVM, MS, DACVNChief of Regulatory & Veterinarian AffairsVeterinary industry veteran: Led teams creating $500M+ in annual product sales at Boehringer Ingelheim, Pfizer, Ceva. Expanded R&D organizations, registered breakthrough vaccines used by vets worldwide., Diego Diel - DVM, MS, PhDChairman of Science Advisory BoardSAB Chairman Dr. Diego Diel: Cornell Associate Professor with 20+ years translating virology research into vaccine solutions. Expert in viral immune evasion mechanisms critical to Kermode's approach.
Amount Raised : $73,211
Reveal the Score by Voting
＿
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
ⓘ
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
ⓘ
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
ⓘ
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
ⓘ
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

A CAFES (Contract and Future Equity Stake) can convert into different types of equity upon a Triggering Event, such as: common or preferred stock for a corporation, limited partnership interest for a limited partnership and membership interest for a limited liability company. At the time of the Triggering Event, the specific rights and limitations associated with the equity stake being issued to the investors will be determined and disclosed by the Entrepreneur.

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment